Photocure fundamentale forhold (PHO)

myk · juli 7, 2021, 9:51am

De sier ingen ting om agenda, er det oppkjøp på gang?

TyrionIV · juli 7, 2021, 9:53am

Bytte en person i valgkomiteen.

Otard · juli 7, 2021, 9:55am

Viktig sak

CanonBoy · juli 7, 2021, 9:59am

“Jónas Einarsson fratrer som medlem av valgkomiteen.
Robert Blatt velges som nytt medlem til valgkomiteen
med en valgperiode frem til ordinær generalforsamling
2022.
Etter dette består valgkomiteen av:
− Hans Peter Bøhn, leder
− Lars Viksmoen, medlem
− Robert Blatt, medlem
med en valgperiode frem til ordinær
generalforsamling i 2022.”

Ingen andre saker foreligger til behandling

rosk82 · juli 7, 2021, 10:06am

Both Jónas Einarsson (Nomination Committee Member) and Anders Tuv (Board Member) represent the same shareholder in Photocure (Radforsk). While not clearly in breach with governance guidelines, we have concluded that the situation is not optimal and could potentially give rise to conflicts of interest.

At the same time, New York based Briarwood Chase Management LLC has emerged as a leading shareholder of Photocure, and the company has invited them to join the Nomination Committee aspart of the company’s strategy to continue internationalising its shareholder base and governance.

They have proposed Robert Blatt as a new member to the Nomination Committee.
Robert Blatt is a partner at Briarwood Chase Management (BCM). Prior to joining BCM, Mr. Blatt was a long-short analyst at Paulson & Co., a multi-billion-dollar hedge fund located in New York. He began his career at Bain Capital at the firm’s multi-billion-dollar flagship North American Private Equity fund. He is a Princeton University graduate and a CFA Charter holder. Robert currently serves on the nomination board of Basware OYJ, a publicly listed software company in Finland.

Briarwood Chase Management LLC is a SEC-registered investment adviser based in New York City. The firm was founded in 2013 by Aalap Mahadevia, who serves as managing partner and oversees all investment activity.

myk · juli 7, 2021, 10:06am

Så flott å få en slik mann ombord. Da kommer det sikkert noen av betydning inn i styret også.

TekBot · juli 7, 2021, 10:05am

Photocure ASA - Notice of an extraordinary general meeting 28 July 2021 - Correction

Oslo, Norway, 7 July 2021: Photocure ASA (OSE: PHO), calls for an extraordinary
general meeting of Photocure to be held in Advokatfirmaet Selmer AS’ premises in
Tjuvholmen allé 1, 0252 Oslo on 28 July 2021 at 17:00 hours (CEST).
…

Vis børsmeldingen

The notice convening the extraordinary general meeting, including the agenda and
the nomination committee’s proposal to the matter to be dealt with, is enclosed*
with this notification and will be sent to all shareholders with known
addresses.
*New attachment from Nomination Committee

Relevant documents referred to in the notice are made available on
www.photocure.com.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA Photocure:
The Bladder Cancer Company delivers transformative solutions to improve the
lives of bladder cancer patients. Our unique technology, which makes cancer
cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Savepig · juli 7, 2021, 11:21am

Ser på dette som et positivt lite steg i reisen til photocure

Otard · juli 13, 2021, 6:34am

Nyheter fra PHO; Prøver tatt av 136 pasienter avslørte 32 kreft tilfeller hvorav 14 av de kun ble funnet med blålys.
Sterkt tegn på snarlig SOC:

Ebitor · juli 13, 2021, 4:38pm

Høy signifikans altså

TekBot · juli 28, 2021, 3:37pm

Photocure ASA - Extraordinary general meeting held

Oslo, Norway, 28 July 2021: Photocure ASA (OSE: PHO), held an extraordinary
general meeting on 28 July 2021 at 17:00 hours (CEST).

…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the
extraordinary general meeting dated 7 July 2021, including the election of
Robert Blatt as new member of the nomination committee. The minutes from the
general meeting are attached hereto.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA:
The Bladder Cancer Company delivers transformative solutions to improve the
lives of bladder cancer patients. Our unique technology, which makes cancer
cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · august 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Snoeffelen (171 likes)

@Rodjer (161 likes)

@rosk82 (63 likes)

Resten av topp 10:

@Savepig (56 likes)
@tooeasy891 (33 likes)
@HeldigFyr (30 likes)
@CanonBoy (30 likes)
@Hayen (26 likes)
@Otard (25 likes)
@togulle (24 likes)

Gratulerer!

TekBot · august 4, 2021, 1:42pm

Photocure ASA: Invitation to presentation of second quarter and first half year 2021 financial results

Oslo, Norway, 4 August 2021: Photocure ASA (Photocure, PHO: OSE) will announce
the second quarter and first half year 2021 financial results on Wednesday 11
August 2021 at 07:30 CET and invites investors, analysts and the media to a
…

Vis børsmeldingen

presentation at 14:00 CET the same day.

The investor presentation will be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event.
The quarterly report and presentation will be published at 07:00 CET and will be
publicly available at www.photocure.com. The streaming event is available
through https://channel.royalcast.com/landingpage/hegnarmedia/20210811_2/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · august 11, 2021, 5:31am

Photocure ASA: Results for the second quarter of 2021

Oslo, Norway, 11 August 2021: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 88.9 million in the second quarter of 2021
(Q2 2020: NOK 53.5), and EBITDA of NOK 5.8 million (NOK -8.9 million), driven by
…

Vis børsmeldingen

growth in the U.S. segment and the continued successful launch in European
markets reacquired in 2020. Despite business challenges due to ongoing surges of
Covid-19 and its variants in certain territories, Photocure plans to increase
investment in commercial activities in the second half of 2021 to capitalize on
improving access to care and to further penetrate the large potential market
opportunity for Hexvix/Cysview in its direct global markets.

“Photocure achieved year over year Hexvix/Cysview revenue growth of 66% in the
second quarter of 2021, driven by a recovery from the comparable period in 2020
when Covid-19 first surged, our reacquisition of the Hexvix business in
continental Europe, and our ability to capitalize on improving healthcare access
in several of our commercial territories. Excluding the impact of negative
foreign exchange, product sales were up 87% over the second quarter last year.
We continued to increase our penetration into the bladder cancer treatment
market, with U.S. unit volume rising 19% sequentially, from the first quarter to
the second quarter of this year. In May, we achieved the highest number of units
ever sold per month in our U.S. business, and in Europe, unit volume in the
second quarter nearly returned to the same level seen in the 2019 period, with
renewed sales activity in priority growth markets such as France and the UK,”
says Daniel Schneider, President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 90.4 million in the second
quarter of 2021 (NOK 53.7 million), and an EBITDA* of NOK 5.8 million (NOK -8.9
million). Hexvix/Cysview revenues were NOK 88.9 million (NOK 53.5 million)
following the successful transition of the reacquired European territories and
unit sales growth of 53% in the U.S. EBIT ended at NOK -0.2 million (NOK -14.2
million) and the cash balance at the end of the second quarter 2021 was NOK
340.2 million.

The installed base of rigid cystoscopes in the U.S. was 288 at the end of the
second quarter, an increase of 42 units or 17% since the same period in 2020.
Blue Light Cystoscopy in the surveillance setting is a key priority for
Photocure in the U.S. market. By the end of the second quarter, a total base of
42 flexible cystoscopes have been installed giving more patients access to the
procedure with less constraints.

"The positive EBITDA in the second quarter was driven by our strong revenue
performance, as well as constrained spending levels as the pandemic continued to
restrict some of our commercial and corporate activities. As a result, our cash
balance increased during the quarter by NOK 10.8 million to NOK 340.2 million.
For the second half of 2021, Photocure plans to increase investment in
commercial activities to capitalize on improving access to care and to further
penetrate the large potential market opportunity for Hexvix/Cysview in our
direct global markets, " Schneider adds.

In Europe and parts of the U.S., hospitals are preparing for the recent surge in
Covid-19 Delta variant cases, referred to as the “fourth wave”. As a result, key
markets in the U.S. and Europe are expected to continue to be impacted by the
Covid-19 pandemic.

“Despite the ongoing effects of Covid-19 and its variants, I am pleased with the
company’s performance in the first half of 2021. I believe that the rebound in
kit volume that we saw in the second quarter is a good indication of our ability
to return to strong organic growth rates once the pandemic is better controlled
and global access to healthcare stabilizes. For now, the environment for revenue
development remains less clear given the latest surge in new Covid-19 Delta
cases. We remain focused on our priorities to help more patients suffering from
bladder cancer benefit from our proven solution, and to create value for our
shareholders as we pursue our vision to become a leader in the bladder cancer
treatment segment,” Schneider concludes.

Please find the full financial report and presentation enclosed.

*EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
first quarter 2021 financial report on page 25.

Photocure will present its second quarter 2021 report on Wednesday 11 August
2021 at 14:00 CET. The investor presentation will be streamed live and be hosted
by Daniel Schneider, CEO and Erik Dahl, CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20210811_2/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure. (ed@photocure.com)com (ed@photocure.com)

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

This stock exchange announcement was published by Tolv Hillestad, Group
Controller, Photocure ASA, on 11 August 2021 at 07:30 CET.

Kilde

busk1 · august 16, 2021, 6:56am

TekBot · august 23, 2021, 8:12pm

Photocure ASA - Share option grant

Oslo, Norway, 23 August 2021 - The board of directors in Photocure ASA (the
“Company”) (OSE: PHO) has granted share options to employees.

…

Vis børsmeldingen

A total of 709,500 share options, equal to 2.6% of total shares issued in the
Company, were granted at an exercise price at NOK 145.27. The option grant is
conditional for 607,500 of the options, and the number of options that may be
exercised by each employee will be determined by the board of directors after
approval of the annual financial statements for 2021. The remaining 102,000
options are granted in relation to new hires.

The options are granted in accordance with Photocure’s long term incentive
program and the board of directors’ declaration on salaries and other
remuneration to the senior executive management, as approved by Photocure’s
annual general meeting held 20 May 2021. The share option program and properties
of the options are described in note 7 and 23 to the annual financial statements
for 2020.

Of the total grant the following was granted to primary insiders (total holdings
of share options following this grant):

· Daniel Schneider, President and Chief Executive Officer, 135,000 options.
Following the issue, Daniel Schneider holds 295,000 share options and 70,254
shares in the Company.
· Erik Dahl, Chief Financial Officer, 67,500 options. Following the issue,
Erik Dahl holds 122,500 share options and 26,863 shares in the Company.
· Geoffrey Coy, Vice President and General Manager of US Operations, 67,500
options. Following the issue, Geoffrey Coy holds 170,000 share options and 8,081
shares in the Company.
· Grete Hogstad, Vice President Strategic Marketing & Business Development,
40,000 options. Following the issue, Grete Hogstad holds 77,500 share options
and 30,719 shares in the Company.
· Patricia Kelly, Vice President Global Human Resources, 40,000 options.
Following the issue, Patricia Kelly holds 80,000 share options in the Company.
· Susanne Strauss, Vice President and General Manager of Europe Operations,
67,500 options. Following the issue, Susanne Strauss holds 157,500 share options
in the Company.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

Ebitor · august 23, 2021, 10:50pm

Opsjonshysteriet i gang igjen i PHO.
Tror dette var planlagt rundt Q2.

Men det er et godt stykke opp til at opsjonene skal gi gevinst.

Target er 145,27

TekBot · august 30, 2021, 10:28am

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 30 August 2021: Participants in Photocure ASA’s (“Photocure” or
the “Company”) share option program have on 30 August 2021 exercised a total of
25,500 options distributed as follows:
…

Vis børsmeldingen

· 3,000 options exercised according to the option program for 2019 at a strike
price of NOK 50.72; and
· 22,500 options exercised according to the option program for 2019 at a
strike price of NOK 56.83.

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 23 in Photocure’s annual financial statements for
2020.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company’s Annual General Meeting, has decided to increase the
Company’s share capital by NOK 12,750 by issuing 25,500 new shares, of par value
NOK 0.50. Subsequent to the transaction, Photocure’s share capital will be NOK
13,471,910 divided into 26,943,820 shares, each share having a par value of NOK
0.50 and carrying one vote in the Company’s general meeting.

22,500 options are exercised by primary insider of the Company Geoffrey Coy, VP
& General Manager US Operations:

Primary insider notification pursuant to the market abuse regulation article 19
is attached.

The primary insider mentioned above has transferred his rights to receive shares
resulting from the exercise of options to a third party. Following a sale of
shares, the primary insider will receive the net proceeds after deduction of the
strike price and accrued tax. The primary insider will use the full net proceeds
to purchase shares in Photocure. The sales amount and the number of shares
purchased will be finally determined on the basis of the price subsequently
obtained by the third party in the market. The results of the sales process will
be announced in a separate stock exchange notice when known.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

Ebitor · august 30, 2021, 10:54am

Ja, ja

Så var det på’n igjen - opsjonshysteriet.
Det er vel det PHO er mest kjent for

Et betimelig spørsmål

Er det fortjent?

CanonBoy · august 30, 2021, 10:51am

Tja, Mr. Coy skal vel kjøpe aksjer for hele fortjenesten.
…“The primary insider will use the full net proceeds
to purchase shares in Photocure.”